Zogenix Inc

Zogenix — Investor Presentation (January 2016)

27 slides from Zogenix's investor presentation, Jan 11, 2016

  1. Slide 1: Company Overview January 2016

    Company Overview January 2016 NASDAQ: ZGNX Exhibit 99.1

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements Zogenix cautions you that statements included in this presentation that are not a description of historical facts are forward-looking statements. Words such as "believes," "plans," "expects," "will," "potential" and similar expressions are intended to identify forward-look

  3. Slide 3: Developed, Commercialized and Monetized CNS Products

    Developed, Commercialized and Monetized CHRONIC PAIN ACUTE MIGRAINES EPILEPSY (DRAVET SYNDROME) SCHIZOPHRENIA ONCE-MONTHLY ZX008 (low-dose fenfluramine) Late Stage Development Global Opportunities Products for the Treatment of CENTRAL NERVOUS SYSTEM (CNS) Disorders

  4. Slide 4: The Zogenix Opportunity

    The Zogenix Opportunity PROMISING PIPELINE of Differentiated CNS Compounds in Late-Stage Clinical Development FULLY FUNDED For Multiple Milestones Through 2017 for 2 Clinical Programs EXPERIENCED TEAM with Successful Track Record of Drug Development HIGHLY EFFICIENT Path to Commercialization and Pro

  5. Slide 5: ZX008 Dravet Syndrome Phase 3

    Worldwide Rights Orphan Drug Designation in U.S. and E.U. Expect to Commercialize Directly in U.S. and E.U. Asia-Pacific Partnering Opportunity ZX008 Dravet Syndrome PHASE 3 START Q4 2015

  6. Slide 6: Dravet Syndrome: A Catastrophic Illness

    Dravet Syndrome: A Catastrophic Illness Intractable, Severe Epilepsy Which Begins In Infancy SIGNIFICANT CHILDHOOD MORTALITY Estimated 16,000 - 29,000 Patients in the U.S. and E.U.1 Approximately 75 Specialty Treatment Centers in U.S. and similar in E.U. Does not Effectively Respond to Traditional E

  7. Slide 7: First Published Study of Fenfluramine Efficacy in Dravet Syndrome

    First Published Study of Fenfluramine Efficacy in Dravet Syndrome Long-term open-label study of fenfluramine as an adjunctive anticonvulsant therapy 12 Dravet syndrome patients, 11 with confirmatory genetic mutation 70% of patients seizure-free at last assessment Range of 1-19 years of seizure freed

  8. Slide 8: Multi-Year Follow-Up Analysis Further Supports Fenfluramine Efficacy

    This analysis includes 10 patients from the original cohort (5 years of follow-up) and 2 patients who began treatment in 2011 (4 years of follow-up) Patients age range of 9 months to 13 years at treatment initiation Multi-Year Follow-Up Analysis Further Supports Fenfluramine Efficacy in Dravet Syndr

  9. Slide 9: Recent Clinical Data Presented at the American Epilepsy Society Meeting

    Recent Clinical Data Presented at the American Epilepsy Society Meeting, December 2015 New data from 7 new Dravet syndrome patients who started fenfluramine after 2010 Low-dose Fenfluramine Significantly Reduces Seizure Frequency in Dravet Syndrome: A Prospective Study of a New Cohort of Belgian Pat

  10. Slide 10: Seizure Reduction in the New Patient Cohort

    Seizure Reduction in the New Patient Cohort AES, 2015 Over the entire observation period (median 0.9 years; range 0.2 to 3.9 years) the median frequency of TC seizures was 0.9 per month, representing an 84% reduction compared to the 3 month run-in period

  11. Slide 11: Cardiac Safety in the New Patient Cohort

    Cardiac Safety in the New Patient Cohort AES, 2015 Patient number Gender (M/F) Current Age (yr) Current weight (kg) Age at start with FFA (yr) Starting Dose FFA (mg/d) Current Dose FFA (mg/d) Duration of Treatment (mo) Number of echocardiography examinations* Echocardiography findings Signs suggesti

  12. Slide 12: Pre-Clinical Evidence of Fenfluramine Activity in Dravet Model

    Pre-Clinical Evidence of Fenfluramine Activity in an Established Model of Dravet Syndrome Zhang, Yifen, et al. PLOS May 12, 2015. Pharmacological Characterization of an Antisense Knockdown Zebrafish Model of Dravet Syndrome: Inhibition of Epileptic Seizures by the Serotonin Agonist Fenfluramine. Zeb

  13. Slide 13: Phase 3 Development Program Initiated

    Phase 3 Development Program Initiated First Placebo-Controlled Phase 3 Trial Started in Jan 2016 FDA approved IND, Dec 2015 Request for Fast Track Designation in the U.S. recently submitted North American (US, Canada) efficacy study initiated Jan 2016 CTA for EU sites in second study (Study 1502) su

  14. Slide 14: ZX008 Phase 3 Study Design

    ZX008 Phase 3 Study Design Two identical efficacy studies, with long term open label extension 6 WEEKS BASELINE OBSERVATION 12 WEEKS TREATMENT Initial Screen Placebo Open Label Safety Study N = 105 Ages 2 – 18 ZX008 0.8 mg/kg/d ZX008 0.2 mg/kg/d 1:1:1 Randomization 2 week Titration

  15. Slide 15: Key Efficacy Assessments

    Key Efficacy Assessments Primary analysis will compare ZX008 0.8 mg/kg/day vs placebo Change in incidence of convulsive seizures during combined titration and maintenance periods compared with baseline observation period Planned secondary analyses include: Comparison of ZX008 0.2 mg/kg/day with plac

  16. Slide 16: Key Safety Assessments

    Key Safety Assessments Adverse events Laboratory safety parameters (hematology, chemistry, urinalysis) Vital signs Cardiac examination Doppler echocardiogram 12-lead electrocardiogram

  17. Slide 17: FDA Agreement on Use of Echocardiography in ZX008 Clinical Program

    FDA Agreement on Use of Echocardiography in ZX008 Clinical Program Lack of precedent for use of prospective echocardiography for safety monitoring in pediatric development program Clinical studies show a high incidence of cardiac valve regurgitation (pulmonary, tricuspid valves) detected in normal h

  18. Slide 18: Market Research: ZX008 Could be Used as First or Second Adjunct Therapy

    E.U. 57% Market Research: ZX008 Could be Used as First or Second Adjunct Therapy in Dravet Syndrome % of Neuros Who Would Use ZX008 as a 1st or 2nd Adjunct Therapy Source: BioStrategies Market Research, May 2015 13 of 16 8 of 14 U.S. 81% Neurologists… Were Overwhelmingly Positive Regarding the Safet

  19. Slide 19: Established Product Protection

    Established Product Protection ORPHAN DRUG STATUS May Provide 10 Years of Market Exclusivity in E.U. and 7 Years in U.S. When Obtained in Japan, ODS Will Provide 10 Years Exclusivity PATENTS PENDING(1) Use of Fenfluramine in Dravet Syndrome and Elements of a Future REMS Program Ongoing Preclinical &

  20. Slide 20: Potential Use of ZX008 in Other Pediatric Orphan Refractory Epilepsy Conditions

    Potential Use of ZX008 in Other Pediatric Orphan Refractory Epilepsy Conditions Investigator Initiated Study (IIS) in Lennox Gastaut syndrome (Professors Lagae and Ceulemans) Open Label Trial - study protocol recently approved by Belgian Regulatory Authority (FAGG) Planned start in Q1 2016 Further r

  21. Slide 21: Proprietary Subcutaneous Once-Monthly Antipsychotic

    Proprietary Subcutaneous Once-Monthly Antipsychotic Highly Differentiated Profile Worldwide Rights Partnering Process Initiated Co-Development/Commercialization Opportunity Schizophrenia PHASE 3 READY

  22. Slide 22: Market Overview of LAIs for Treatment of Schizophrenia

    Market Overview of LAIs for Treatment of Schizophrenia 2.4 Million Diagnosed Patients in the U.S. Treatment Compliance Can Be Challenging Treatment Paradigm Evolving Towards Earlier Use of LAIs LAIs for Schizophrenia PATIENTS PHYSICIANS Large, Growing $3.8B WW Market Highly Concentrated U.S. Market

  23. Slide 23: RELDAY Has a Differentiated LAI Profile

    RELDAY Has a Differentiated LAI Profile Overcomes complexities associated with other long acting injections No oral supplementation / complicated loading dose regimens Initiation dose identical to maintenance dose Once-monthly dosing interval Subcutaneous administration Potential for improved safety

  24. Slide 24: Development Progress to Date

    Development Progress to Date Strong physician and payer endorsement Single-Dose Study Successfully Completed Multi-Dose Study Successfully Completed Issued and Pending Patents Through at Least 2034 Formulation Technology also Amenable to Three-Monthly Dosing Interval for Future Development and Life-

  25. Slide 25: Focused on Execution in Late-Stage Development

    2017 2016 Q1 Q2 Q3 Q4 Focused on Execution in Late-Stage Development ZX008 Initiate US Ph 3 Trial for DS Initiate EU Ph 3 Trial for DS EU Phase 3 Results Target DS NDA/MAA Submissions Potential Partnership End of Ph 2 FDA Meeting Initiate Ph 3 with Partner Top Line Data from US Ph 3 Trial for DS II

  26. Slide 26: Financial Highlights

    Financial Highlights Cash ( balance at 12-31-15) $155.9 M Debt (1) (as of 12-31-15) $20.0 M Common Shares Outstanding 24.8 million Fully Diluted Shares (2) 29.5 million Excludes $7.0 million working capital advance from Endo International Fully diluted shares include options to purchase 2.7 million

  27. Slide 27: PROMISING PIPELINE FULLY FUNDED CLINICAL PROGRAMS EXPERIENCED, SUCCESSFUL TEAM SIGNIFICANT NEAR-TERM MILESTONES HIGHL…

    NASDAQ: ZGNX PROMISING PIPELINE FULLY FUNDED CLINICAL PROGRAMS EXPERIENCED, SUCCESSFUL TEAM SIGNIFICANT NEAR-TERM MILESTONES HIGHLY EFFICIENT PATH TO COMMERCIALIZATION

Zogenix — Investor Presentation (January 2016) on 6ix